IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant:	GAZIT Ehud et al	§	
Serial No.:	US National Phase of PCT/IL 2004/000898	§	
Filed:	Herewith	§	Group Art Unit: Not Yet Assigned
For:	Novel Antibacterial Agents And Methods Of Identifying And Utilizing Same	§	Attorney Docket: 31689
Examiner:	Not Yet Assigned	§	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Martin D. Moynihan
Registration No. 40,338

Dated: March 31, 2006

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.A./

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known	
Application Number	US National Phase of PCT/IL 2004/000895
Filing Date	Herewith
First Named Inventor	Ehud GAZIT et al
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	31689

Sheet 1 of 4

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US-6,359,112	03-19-2002	Kapurniotu et al.	
	2	US-3,791,932	02-12-1974	Schuurs et al.	
	3	US-3,853,987	12-10-1974	Dreyer	
	4	US-4,873,316	10-10-1989	Meade et al.	
	5	US-4,666,828	05-19-1987	Gusella	
	6	US-4,683,202	07-28-1987	Mullis	
	7	US-4,801,531	01-31-1989	Frossard	
	8	US-5,192,659	09-9-1993	Simons	
	9	US-5,272,057	12-21-1993	Smulson et al.	
	10	US-3,839,153	01-1-1974	Schuurs et al.	
	11	US-3,850,752	11-26-1974	Schuurs et al.	
	12	US-3,850,578	11-26-1974	McConnnell	
	13	US-3,867,517	02-18-1975	Ling	
	14	US-3,879,262	04-22-1975	Schuurs et al.	
	15	US-3,901,654	08-26-1975	Gross	
	16	US-3,935,074	01-27-1976	Rubenstein et al.	
	17	US-3,984,533	05-5-1976	Uzgiris	
	18	US-3,996,345	07-7-1976	Ullman et al.	
	19	US-4,034,074	05-5-1977	Miles	
	20	US-4,098,876	04-4-1978	Piasio et al.	
	21	US-4,879,219	07-7-1989	Wands et al.	
	22	US-5,011,771	04-30-1991	Bellet et al.	
	23	US-5,281,521	01-25-1994	Trojanowski et al.	
	24	US-6,303,567	10-16-2001	Findeis et al.	
	25	US-2004/0052928	03-18-2004	Gazit	
	26	US-2005/0020809	01-27-2005	Gazit	
	27	US-5,688,561	11-18-1997	Ichikawa et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Documents Country Code[3] Number[4] Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	28	EP 0264166	04-20-1988	Gordon et al.		
	29	PCT WO 2004/052773	06-24-2004	Reches et al.		
	30	PCT WO 2004/060791	07-22-2004	Gazit et al.		
	31	PCT WO 99/58652	11-18-1999	Gerdes et al.		
	32	PCT WO 01/10457	02-15-2001	Vahlne		
	33	PCT WO 80/00789	01-1-1980	Chu et al.		
	34	PCT WO 03/063760	07-7-2003	Gazit		
	35	PCT WO 2005/000193	06-6-2005	Gazit		

Examiner Signature		Date Considered	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.A./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known	
Application Number	US National Phase of PCT/IL 2004/000898
Filing Date	Herewith
First Named Inventor	Ehud GAZIT et al
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	31689

Sheet 2 of 4

Examiner Initials	Cite No.[1]	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	36	Hartgerink et al. "Self-Assembling Peptide Nanotubes", Journal of the American Chemical Society, 118: 43-50, 1996.	
	37	Ajayan et al. "Applications of Carbon Nanotubes", Topics of Applied Physics, 80: 391-425, 2001.	
	38	Booth et al. "Instability, Unfolding and Aggregation of Human Lysozyme Variants Underlying Amyloid Fibrillogenesis", Nature, 385: 787-793, 1997.	
	39	Glenner "Amyloid Deposits and Amyloidosis. The Beta-Fibrilloses (First of Two Parts)", The New England Journal of Medicine, 302(23): 1283-1292, 1980.	
	40	Ferrannini "Insulin Resistance Versus Insulin Deficiency in Non-Insulin-Dependent Diabetes Mellitus: Problems and Prospects", Endocrine Reviews, 19(4): 477-490, 1998.	
	41	Westermark "Amyloid and Polypeptide Hormones: What is Their Interrelationship?", Amyloid Int. J. Exp. Clin. Invest, 1: 47-60, 1994.	
	42	Westermark "Islet Amyloid Polypeptide: Pinpointing Amino Acid Residues Linked to Amyloid Fibril Formation", Proc. Natl. Acad. Sci. USA, 87: 5036-5040, 1990.	
	43	Johnson et al. "Islet Amyloid, Islet-Amiloid Polypeptide, and Diabetes Mellitus", The New England Journal of Medicine, 321(8): 513-518, 1989.	
	44	Mosselman et al. "Islet Amyloid Polipeptide: Identification and Chromosomal Localization of the Human Gene", FEBS Letters, 239(2): 227-232, 1988.	
	45	Moriarty et al. "Effects of Sequential Proline Substitutions on Amoyloid Formation by Human Amylin20-29", Biochemistry, 38: 1811-1818, 1999.	
	46	Höppener et al. "Islet Amyloid and Type 2 Diabetes Mellitus", The New England Journal of Medicine, 343(6): 411-419, 2000.	
	47	Seino "S20G Mutation of the Amylin Gene Is Associated With Type II Diabetes in Japanes", Diabetologia, 44: 906-909, 2001.	
	48	Gillmore et al. "Amyloidosis A Review of Recent Diagnostic and Therapeutic Developments", British Journal of Haematology, 99: 245-256, 1997.	
	49	Kulkarni et al. "Investigation of the Efffect of Antisense Oligodeoxynucleotides to Islet Amyloid Polypeptide mRNA on Insulin Release, Content and Expression", Journal of Endocrinology, 151: 341-348, 1996.	
	50	Novials et al. "Reduction of Islet Amylin Expression and Basal Secretion by Adenovirus-Mediated Delivery of Amylin Antisense cDNA", Pancreas, 17(2): 182-186, 1998.	
	51	Kahn et al. "Islet Amyloid: A Long-Recognized But Underappreciated Pathological Feature of Type 2 Diabetes", Diabetes, 48: 241-253, 1999.	
	52	Merlini et al. "Intereaction of the Anthracycline 4'-Iodo-4'-Deoxydoxorubicin With Amyloid Fibrils: Inhibition of Amyloidogenesis", Proc. Natl. Acad. Sci. USA, 92: 2959-2963, 1995.	
	53	Soto et al. Beta-Sheet Breaker Peptides Inhibit Fibrillogenesis in A Rat Brain Model of Amyloidosis: Implications for Alzheimer's Therapy", Nature Medicine, 4(7): 822-826, 1998.	
	54	Tenidis et al. "Identification of A Penta- and Hexapeptide of Islet Amyloid Polypeptide (IAPP) With Amyloidogenic and Cytotoxic Properetie", Journal of Molecular Biology, 295(4): 1055-1071, 2000.	
	55	Kuner et al. "Controlling Polmerization of Beta-Amyloid and Prion-Derived Peptides With Synthetic Smal Molecule Ligands", Journal of Biological Chemistry, 275(3): 1673-1678, 2000.	
	56	Findeis "Approaches to Discovery and Characterization of Inhibitors of Amyloid Beta-Peptide Polymerization", Biochimia & Biophysica Acta, 1502: 76-84, 2000.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.A./

	57	Wilesmith et al. "Bovine Spongiform Encephalopathy", Current Topics in Microbiology & Immunology, 172: 21-38, 1991.	
	58	Gajdusek "Unconventional Viruses and the Origin and Disappearance of Kuru", Science, 197(4307): 943-960, 1977.	
	59	Medora et al. "Fatal Familial Insomnia, A Prion Disease With A Mutation at Codon 178 of the Prion Protein Gene", The New England Journal of Medicine, 326(7): 444-449, 1992.	
	60	Pinkert et al. "An Albumin Enhancer Located 1o Kb Upstream Functions Along With Its Promoter to Direct Efficient, Liver-Specific Expression in Transgenic Mice", Genes & Development, 1: 268-276, 1987.	
	61	Calame et al. "Transcriptional Controlling Elements in the Immunoglobulin and T Cell Receptor Loci", Advances in Immunology, 43: 235-275, 1988.	
	62	Winoto et al. "A Novel, Inducible and T Cell-Specific Enhancer Located at the 3' End of the T Cell Receptor Alpha Locus", The EMBO Journal, 8(3): 729-733, 1989.	
	63	Banerji et al. "A Lymphocyte-Specific Cellular Enhancer Is Located Downstream of the Joining Region in Immunoglobulin Heavy Chain Genes", Cell, 33: 729-740, 1983.	
	64	Byrne et al. "Mutiplex Gene Regulation: A Two-Tiered Approach to Transgene Regulation in Transgenic Mice", Proc. Natl. Acad. Sci. USA, 86: 5473-5477, 1989.	
	65	Edlund et al. "Cell-Specific Expression of the Rat Insuline Gene: Evidence for Role of Two Distinct 5' Flanking Elements", Science, 230(4278): 912-916, 1985.	
	66	Bursavich et al. "Designing Non-Peptide Peptidomimetics in the 21st Century: Inhibitors Targeting Comformational Ensembles", Journal of Medical Chemistry, 45(3): 541-558, 2002.	
	67	Baltzer et al. "De Novo Design of Proteins - What Are the Rules?", Chem. Rev., 101(10): 3153-3163, 2001.	
	68	Orlandi et al. "Cloning Immunoglobulin Variable Domains for Expression by the Polymerase Chain Reaction", Proc. Natl. Acad. Sci. USA, 86: 3833-3837, 1989.	
	69	Winter et al. "Man-Made Antibodies", Nature, 349: 293-299, 1991.	
	70	Kohler et al. "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specifity", Nature, 256: 495-497. 1975.	
	71	Kozbor et al. "Specific Immunoglobulin Production and Enhanced Tumorigenicity Following Ascites Growth of Human Hybridomas", Journal of Immunological Methods, 81: 31-42, 1985.	
	72	Cote et al. "Generation of Human Monoclonal Antibodies Reactive With Cellular Antigens", Proc. Natl. Acad. Sci. USA, 80: 2026-2030, 1983.	
	73	Cole et al. "Human Monoclonal Antibodies", Molecular &. Cellular Biochemistry, 62(2): 109-120, 1984.	
	74	Han et al. "Technetium Complexes for the Quantitation of Brain Amyloid", J. Am. Chem. Soc., 118: 4506-4507, 1996.	
	75	Sambrook et al. "Molecular Cloning: A Laboratory Manual", 2nd Edition, Cold Spring Harbor Laboratory,1989.	
	76	Ausubel et al. Current Protocols in Molecular Biology, 1 (Suppl.63).	
	77	Perbal "A Practical Guide to Molecular Cloning", Wiley-Interscience Publication.	
	78	Stites et al. Basic & Clinical Immunology, 8th Edition.	
	79	Gait "Oligonucleotide Synthesis - A Practical Approach", IRL Press.	
	80	Freshney "Animal Cell Culture - A Practical Approach", IRL Press.	
	81	Marshak et al. "Strategies for Protein Purification and Charcterization, A Laboratory Course Manual", Cold Spring Harbor Laboratory Press, 1996.	
	82	Cooper "Selective Amyloid Staining As A Function of Amyloid Composition and Structure. Histochemical Analysis of the Alkaline Congo Red. Standardized Toluidine Blue, and Iodine Methods", Laboratory Investigation, 31(3): 232-238, 1974.	
	83	Gorman et al. "Alzheimer ß-Amyloid Peptides, Structures Of Amyloid Fibrils and Alternate Aggregation Products", Biopolymers, 60: 381-394, 2001. Claims: 1-16, 22-26, 70-80, 91-100.	
	84	Kapurniotu et al. DATABASE, Accession No. AAW93015, 1991. Claims: 1-16, 22-26.	
	85	Hoeppener et al. "The Complete Islet Amyloid Polypeptide Precursor Is Encoded by Two Exons", Biochem. Biophys. Res. Commun., 189: 1569-1577, 1993. DATABASE, Accession No. S04016, 1993. Claims: 1-16, 22-26.	
	86	Stephenson et al. "The 'Promiscuous Drug Concept' With Applications to Alzheimer's Disease", FEBS Letters, 579: 1338-1342, 2005.	
	87	Hayden et al. "'A' Is for Amylin and Amyloid in Type 2 Diabetes Mellitus", JOP. J. Pancreas (Online), 2(4): 124-139, 2001.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.A./

	88	Grady et al. "Axe-Txe, A Broad-Spectrum Proteic Toxin-Antitoxin System Specified by A Multidrug-Resistant, Clinical Isolate of Enterococcus Faecium", Molecular Biology, 47(5): 1419-1432, 2003. Abstract, P.1424, Col.2, P.1426, Col.2, Fig.5.	
	89	Cherny et al. "The YefM Antitoxin Defines A Family of Natively Unfolded Proteins", The Journal of Biological Chemistry, 279(9): 8252-8261, 2004.	
	90	Engelberg-Kulka et al. "Bacterial Programmed Cell Death Systems as Targets for Antibiotics", Trends in Microbiology, 12(2): 66-71, 2004.	
	91	Forloni et al. "Anti-Amyloidogenic Activity of Tetracyclines: Studies In Vitro", FEBS Letters, 487(3): 404-407, 2001. Abstract, Results, Figs.1, 3.	
	92	Lansbury Jr. "Following Nature's Anti-Amyloid Strategy", Nature Biotechnology, 19(2): 112-113, 2001.	
	93	Grateau "Le Curli du Coli: Une Variété Physiologique d'Amylose", Medecine Sciences, 18(6-7): 664, 2002.	
	94	Cherny et al. "The Formation of Escherichia Coli Curli Amyloid Fibrils Is Mediated by Prion-Like Peptide Repeats", Journal of Molecular Biology, 352(2): 245-252, 2005.	
	95	Görbitz "Nanotube Formation by Hydrophobic Dipeptides", Chemistry, 7(23): 5153-5159, 2001.	
	96	Reches et al. "Amyloid Fibril Formation by Pentapeptide and Tetrapeptide Fragments of Human Calcitonin", Journal of Biological Chemistry, 277(38): 35475-35480, 2002.	
	97	Haldar et al. "First Crystallographic Signature of the Highly Ordered Supramolecular Helical Assemblage From A Tripeptide Containing A Non-Coded Amino Acid", Tetrahedron Letters, 43(14): 2653-2656, 2002.	
	98	Maji et al. "Fibril-Forming Model Synthetic Peptides Containing 3-Aminophenylacetic Acid", Tetrahedron, 58(43): 8695-8702, 2002.	
	99	Hartgerink et al. "Peptide Nanotubes and Beyond", Chemistry, A European Journal, 4(8): 1367-1372, 1998.	
	100	Ghadiri et al. "Self-Assembling Organic Nanotubes Based on A Cyclic Peptide Architecture", Nature, 366: 324-327, 1993.	
	101	Horne et al. "A Heterocyclic Peptide Nanotube", Journal of the American Chemical Society, 125(31): 9372-9376, 2003.	
	102	Reches et al. "Casting Metal Nanowires Within Discrete Self-Assembled Peptide Nanotubes", Science, 300(5619): 625-627, 2003.	
	103	Adekore et al. "Carbon Nanotubes", P.1-11, 2001.	
	104	Brauer "GB-245 Nanotubes: Directions and Techno", BCC, P.1-14, 2000.	
	105	Martin et al. "The Emerging Field of Nanotube Biotechnology", Nature Reviews, 2: 29-37, 2003.	
	106	Zhang et al. "Design of Nanostructured Biological Materials Through Self-Assembly of Peptides and Proteins", Current Opinion in Chemical Biology, 6: 865-871, 2002.	
	107	Daenen et al. "The Wondrous World of Carbon Nanotubes", P.1-8, 2003.	
	108	Gazit "Global Analysis of Tandem Aromatic Optapeptide Repeats: The Significance of the Aroma-Glycine Motif", Bioinformatics Discovery Note, 18(6): 880-883, 2002.	
	109	Gazit "The 'Correctly Folded' State of Proteins: Is it a Metastable State ?", Angew. Chem. Int. Ed., 41(2): 257-259, 2002.	
	110	Gazit "A Possible Role for 'Phi'-Stacking in the Self-Assembly of Amyloid Fibrils", FASEB: 77-83, 2002.	
	111	Coughlan et al. "Factors Influencing the Processing and Function of the Amyloid Beta Precursor Protein - A Potential Therapeutic Target in Alzheimer's Disease?", Pharmacology and Therapeutics, 86: 111-144, 2000.	
	112	Damas et al. "Review: TTR Amyloidosis - Structural Features Leading to Protein Aggregation and Their Implications on Therapeutic Strategies", Journal of Structural Biology, 130: 290-299, 2000.	
	113	Gazit "Mechanistic Studies of the Process of Amyloid Fibrils Formation by the Use of Peptide Fragments and Analogues: Implications of the Design of Fibrillization Inhibitors", Current Medicinal Chemistry, 9: 1667-1675, 2002.	
	114	Mazor et al. "Identification and Characterization of A Novel Molecular-Recognition and Self-Assembly Domain Within the Islet Amyloid Polypeptide", Journal of Molecular Biology, 322: 1013-1024, 2002.	

Signature	/Nina Archie/	Considered	11/20/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1. Applicant's unique citation designation number (optional). 2. Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.A./